Best Inside Global Pharma Podcasts (2026)

1
Ep. 100 - Adam Koppel on Why Private Equity Is Moving Deeper Into Biotech and What Comes Next 36:45

Play Pause

17h ago36:45

36:45

Private equity’s expanding role in biopharma as a growth equity investor reflects both the maturation of the life sciences sector and the rising need for large-scale capital, alongside PE firms’ increasing ability to conduct the technical diligence required for investments once considered too risky for their models. In conversation with The BioCent…

1
How to Make a Few More Billion Dollars with Brad Jacobs 25:32

15d ago25:32

25:32

On this episode of The Forum with CNBC’s Becky Quick, Brad Jacobs, Chairman and CEO of QXO, Inc., joins Sara Eisen, Co-Anchor of Squawk on the Street and Money Movers on CNBC, for a conversation on building and scaling multi-billion-dollar companies across industries. Over the course of his career, Jacobs has founded and scaled multiple Fortune 500…

1
Ep. 99 – Stelios Papadopoulos on Biotech’s Long View: Pricing Pressure, China & Big Pharma 37:59

20d ago37:59

37:59

In historical terms, this is not a bear market, says Stelios Papadopoulos. There’s volatility, which is unnerving, and major issues to reckon with, but the level of anxiety in biotech doesn’t reflect the “extraordinary science, the likes of which we’ve never seen — and it’s getting better,” said Papadopoulos on The BioCentury Show. Papadopoulos is …

1
Inside Sionna’s Bid To Normalize CFTR Function 31:33

20d ago31:33

31:33

Send us a text Two leaders from Sionna Therapeutics walk through a 15‑year journey from Genzyme science to a public company advancing NBD1‑targeted therapies in cystic fibrosis. We examine why most patients still fall short of normal CFTR, how a predictive assay de‑risks choices, and what it takes to finance, hire, and execute with patients as the …

1
Ep. 98 - Inside Precision Oncology’s Next Chapter with Fore’s Bill Hinshaw 37:38

1M ago37:38

37:38

When Bill Hinshaw looks back across the arc of his career — from his early days helping to commercialize Gleevec to his present role leading Fore Biotherapeutics — he sees a precision oncology field transformed by technological ambition, yet still grappling with many of the structural challenges that defined its beginnings, now compounded by the di…

1
AI Won’t Replace Writers, But Writers Who Use AI Will Outpace The Rest with Bilal Bham 24:03

1M ago24:03

24:03

Send us a text What if the documents behind a clinical trial were written with the patient’s voice in mind and delivered at the speed modern science deserves? We sit down with writer, consultant, and patient-advocate Bilal Bham to unpack how protocols, clinical trial applications, and clinical study reports actually get made, why structure beats ch…

1
Popular Episode - Reimagining FDA: Steve Usdin on Designing the Drug Regulator of the Future 38:39

1M ago38:39

38:39

This is a previously recorded episode of The BioCentury Show from September 5, 2025. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes. If you could redesign FDA from the ground up, what would it look like? That’s the fundamental question underlying the 2025 BioCentury Bac…

1
Rebuilding Wells Fargo After the Scandal: Inside the Turnaround with Charles Scharf 22:11

1M ago22:11

22:11

On this episode of The Forum with CNBC’s Becky Quick, Wells Fargo Chairman and CEO Charles Scharf joins Sara Eisen, Co-Anchor of Squawk on the Street and Money Movers on CNBC, for a candid conversation on leading one of America’s largest banks through crisis, scandal, and transformation. Drawing from his first years at Wells Fargo, Scharf reflects …

1
From Grief To Global Advocacy For Clinical Research In Infectious Diseases with Christian John Lillis 31:04

2M ago31:04

31:04

Send us a text A routine dental visit, a few days of diarrhea, and then the unthinkable: septic shock and a life lost within 24 hours. Our guest, Christian John Lillis, shares how losing his mother Peggy to a community-acquired C. diff infection exposed a silent public health crisis and led him to co-found the Peggy Lillis Foundation (https://cdiff…

1
Ep. 97 – From NIH to Industry: Zerhouni Warns Policy & Rhetoric Threaten U.S. Science 34:11

2M ago34:11

34:11

Elias Zerhouni personifies the American dream. He arrived in the U.S. from Algeria as a young man with a couple of hundred dollars in his pocket. Talent, ambition and hard work propelled him into a successful academic career. In 2002, he was nominated and confirmed as NIH director, and later he served in senior positions in the biopharma industry. …

1
Inside U.S. Trade Policy: Tariffs, China and Reshoring with Ambassador Jamieson Greer 21:21

2M ago21:21

21:21

On this episode of The Forum with CNBC’s Becky Quick, Ambassador Jamieson Greer, United States Trade Representative, joins Maria Bartiromo, host of Mornings with Maria on FOX Business, for a wide-ranging conversation on the direction of U.S. trade policy and its impact on national security. Greer discusses the goals behind an America First trade st…

1
Ep. 96 – From Pharma Partnering to Biotech CEO: Sophie Kornowski on Boston Pharma’s Playbook 32:17

2M ago32:17

32:17

It took Sophie Kornowski under four years as CEO of Boston Pharma to bring it from a pipeline full of in-licensed assets to an acquisition by GSK for about $2 billion in total deal value for a single MASH program. Though her first gig as a biotech CEO, Kornowski’s success was built on her years of experience as head of partnering at Roche. She disc…

1
Ep. 95 - Kymera CEO Nello Mainolfi: Matching Degrader Chemistry to the Problem 31:33

3M ago31:33

31:33

Kymera Therapeutics has a clear mission: to transform immunology with targeted protein degraders that enable “oral drugs with biologics-like activity,” CEO Nello Mainolfi told The BioCentury Show. A pioneer in one of biopharma’s most closely watched new therapeutic modalities, Kymera is now over nine years into its story, with multiple pharma partn…

1
Ep. 94 - Frazier's James Li on China’s Rapidly Evolving Biotech Deal Landscape 29:45

3M ago29:45

29:45

The frenzy among Western companies to access China’s biotechnology innovation is remaking the landscape for cross-border dealmaking, with assets becoming more expensive and partnerships earlier and broader than ever before. That’s being driven by exceptional capital efficiency, access to patients and speed of development, said Frazier Life Sciences…

1
Trade Wars, Tariffs and National Security with John Bolton, former National U.S. Security Advisor 23:51

3M ago23:51

23:51

On this episode of The Forum with CNBC’s Becky Quick, John Bolton, former U.S. National Security Advisor, shares his perspective on the U.S.–China trade war, tariffs, defense spending, and the challenges of maintaining strong alliances. He also discusses Iran’s nuclear ambitions, the role of proxies in the Middle East, criticism of the United Natio…

1
Ep. 93 – BIO’s Fritz Bittenbender on Trump 2.0, MFN Threats & Pharma’s Concessions 34:03

4M ago34:03

34:03

President Donald Trump’s demands for “most favored nation” drug pricing presents the biopharma industry with an immense public policy challenge. Drug companies are convinced that meeting the president’s demand to reduce U.S. prices to levels below those of other industrialized countries would decimate the industry. On this episode of The BioCentury…

1
Decoding Real-World Evidence: Beyond Clinical Trials with Manfred Stapff 31:41

4M ago31:41

31:41

Send us a text What if millions of electronic health records could transform how we understand medicine? In this thought-provoking conversation with Dr. Manfred Stapff, physician and real-world evidence pioneer, we uncover how anonymized patient data is revolutionizing healthcare research. Dr. Stapff reveals how the 21st Century Cures Act dramatica…

1
Ep. 92 - Reimagining FDA: Steve Usdin on Designing the Drug Regulator of the Future 38:43

4M ago38:43

38:43

If you could redesign FDA from the ground up, what would it look like? That’s the fundamental question underlying the 2025 BioCentury Back to School essay, authored by BioCentury Washington Editor Steve Usdin, who has been a leading voice on regulation and policy for over two decades. The topic is especially meaningful in this era of FDA turmoil, w…

1
Democratizing Drug Development Through AI-Native Platforms with Ilya Burkov 18:32

4M ago18:32

18:32

Send us a text Cloud computing is transforming biotech by offering purpose-built infrastructure that supports AI-driven drug discovery and development while meeting strict regulatory requirements. Dr. Ilya Burkov explains how Nebius provides full-stack solutions that democratize access to powerful technology, enabling researchers to achieve breakth…

1
Ep. 91 – Annalisa Jenkins: How MHRA’s Reset Could Revive U.K. Biotech 36:07

5M ago36:07

36:07

A new head at MHRA, a streamlined government life sciences strategy, and a more sophisticated innovation ecosystem have Annalisa Jenkins optimistic about the future of U.K. biotech — and its potential to carve out a stronger global role. On The BioCentury Show, Annalisa Jenkins, chair of Gemma Biotherapeutics, discussed the evolving landscape of bi…

1
Incorruptible Evidence: Blockchain's Promise for Faster Drug Approvals w. Dominik Lysek 27:44

5M ago27:44

27:44

Send us a text Dominik Lysek, CEO of PharmaTrail, explains how blockchain technology can solve trust issues in clinical trials by providing an incorruptible audit trail that verifies data integrity. This solution could significantly accelerate the time required for regulatory approvals, partnerships, and acquisitions, ultimately getting treatments …

1
Popular Episode - Vertex’s Winning Formula: Altshuler on Choosing the Next Breakthroughs 32:44

5M ago32:44

32:44

This is a previously recorded episode of The BioCentury Show from March 19, 2025. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes. Vertex’s approach to research, defined over a decade ago to beat the dismal odds of success in biotech, remains core to its strategy, even a…

1
Revolutionizing Dentistry: AI and Research Innovation with Dr. Shervin Molayem 38:48

5M ago38:48

38:48

Send us a text Dr. Shervin Molayem shares his journey of innovation in dentistry, starting with his discovery of a connection between periodontal disease and COVID-19 severity that became the world's most-read dental article of 2020. He discusses groundbreaking technologies including AI-powered diagnostic tools and a revolutionary non-surgical trea…

1
The Taco Mentality: Unpacking Today’s Policy Risks with Lawrence Summers and Glenn Hubbard 21:53

5M ago21:53

21:53

On this episode of The Forum with CNBC's Becky Quick, Lawrence Summers and Glenn Hubbard examine the growing disconnect between economic sentiment, policy decisions, and market fundamentals. They explore how tariffs, inflation psychology, and evolving central bank communication may be amplifying uncertainty. From self-inflicted shocks to the rise o…

1
Ep. 90 – Inside Biopharma Dealmaking: ProFound CEO John Lepore on Knowing What Partners Want 33:05

6M ago33:05

33:05

In an environment where everybody hurts, it helps for biotech CEOs to understand the pressures driving pharmas, investors and other key players if they want to secure deals and financings that will help them succeed. That’s how John Lepore, CEO of Profound Therapeutics and former head of research at GSK, is navigating his early stage company throug…

1
Ep. 89 - Delivering on the biosimilars promise, a conversation with Gillian Woollett 31:47

6M ago31:47

31:47

Gillian Woollett, head of regulatory strategy and policy at Samsung Bioepis, discusses how FDA can deliver on its promise to “massively streamline” the regulation of biosimilars. Eliminating unnecessary clinical trial requirements could halve the time and cost of developing a biosimilar, according to Woollett. While regulators around the world are …

1
How early diagnostics of lung cancer can lead to better survival rates with Chris Wood 36:59

6M ago36:59

36:59

Send us a text Chris Wood discusses how early diagnostics of lung cancer through artificial intelligence and medical imaging can lead to better survival rates through early intervention. • Lung cancer takes more lives than breast, prostate and colon cancer combined, with approximately 70% of cases caught at late stages • The National Lung Screening…

1
Navigating Global Uncertainty with Mohamed A. El-Erian 20:43

6M ago20:43

20:43

In this engaging conversation, Mohamed A. El-Erian offers his insights into the potential outcomes for the world economy amidst uncertainty, the U.S.'s role in global trade, and the shifting dynamics of international finance. Additionally, he shares why he believes the economic power balance is shifting and how both emerging markets and the U.S. ar…

1
Ep. 88 – From Satiety to Muscle: Zealand CEO Steensberg on Amylin’s Edge in Obesity 30:41

7M ago30:41

30:41

Mounting clinical evidence suggests amylin agonists could supplant GLP-1 molecules as the foundational backbone of future obesity therapy, says Zealand Pharma CEO Adam Steensberg on The BioCentury Show. One of the leading cardiometabolic biotechs, Zealand received the largest-ever upfront payment in a biotech licensing deal when it partnered its pe…

1
From Hopeless to High-Performing: Transforming Pharma Teams with Rajesh Anandan and Nechama Katan 53:36

7M ago53:36

53:36

Send us a text Building high-performing teams in life sciences requires understanding how neurodiversity can be an advantage and designing work systems that enable different brain types to collaborate effectively. • A high-performing team continues to function when everything around it has fallen apart • Star players can become crutches that mask u…

1
Ep. 87 – Korea’s Biotech Playbook: Orum CEO SJ Lee on Going Global and Creating Novel Therapies 27:41

7M ago27:41

27:41

Globalizing quickly and gaining a first-mover advantage are the winning strategies for South Korean biotechs as they look to compete on the world stage, says Orum Therapeutics founder and CEO SJ Lee in conversation with BioCentury Executive Editor Jeff Cranmer on The BioCentury Show. Lee’s company, a leader in degrader-antibody conjugates, provides…

1
Data Governance in the Age of Generative AI with Sebastian Andruszczak 36:08

7M ago36:08

36:08

Send us a text Sebastian Andruszczak, Chief Growth Officer at Holisticon (part of the Nexer Group), brings fresh perspective to the conversation around generative AI adoption in pharmaceutical companies. Drawing from his unique background in sales, marketing, and technology, Sebastian cuts through the hype to address fundamental challenges that pre…

1
Ep. 86 – Macrophages, ASCO & Clever-1: Faron CEO Juho Jalkanen on Bexmarilimab’s Promise 10:22

7M ago10:22

10:22

The macrophage field has seen its share of setbacks, but Faron believes bexmarilimab, its humanized mAb that binds to immune checkpoint target Clever-1, has what it takes to get across the goal line at FDA. On a special sponsored edition of The BioCentury Show, Juho Jalkanen, founder and CEO of Faron Pharmaceuticals, explains how the Finnish biotec…

1
Ep. 85 - Stifel’s Opler on Trump 2.0's FDA & the Capital Markets 32:39

8M ago32:39

32:39

Notwithstanding the bad start that the Trump administration got off to on FDA, Tim Opler is optimistic that the agency will serve drug developers well, and sees enough good signals that the direction the agency is headed will not bring the difficult regulatory era that many in the industry feared. Opler, a managing director at Stifel, spoke to Edit…

1
Bitcoin: Humanity's Asset with Michael Saylor 19:57

8M ago19:57

19:57

Listen to this insightful episode as Executive Chairman and Co-Founder of Strategy, Michael Saylor, explores how Bitcoin is redefining the future of finance in the digital age. Michael Saylor reveals why he sees Bitcoin not just as digital currency, but as “digital capital” — a revolutionary asset defined by its scarcity, security, and freedom from…

1
Prevention Pays: How Technology Is Revolutionizing Mental Health with Eva Papadopoulou 27:14

8M ago27:14

27:14

Send us a text Why do we wait until we're severely unwell before seeking help? In this thought-provoking episode, I'm joined by Eva Papadopoulou, a mental health professional and expert in digital and AI-enabled healthcare solutions, to explore the transformative potential of preventative mental healthcare. Eva reveals the stark reality of our curr…

1
Ep. 84 – Leadership Amid Turmoil: Moonlake CEO Jorge Santos Da Silva 29:19

8M ago29:19

29:19

As CEO of a vintage 2021 biotech, Jorge Santos Da Silva has had his leadership mettle tested by a pandemic, rising interest rates, a bear market, and a tumultuous U.S. policy environment — all while building the case for Moonlake’s lead program to become a top therapy for hidradenitis suppurativa and, eventually, a “pipeline-in-a-product.” The key …

1
Ep. 83 – Europe’s Biotech Moment: Jérôme van Biervliet on Turning Uncertainty into Opportunity 31:54

8M ago31:54

31:54

Europe did not ask for this opportunity, says VIB’s Jérôme van Biervliet, but with FDA and the U.S. research funding situation headed into uncertain territory, it needs to use this moment to capitalize on its strengths in research, and address the shortcomings of its business and regulatory systems that have made it hard for biotech to fulfill its …

1
Shaping The Future: AI and Meritocracy with Alex Karp 15:06

9M ago15:06

15:06

Listen to this thought-provoking episode as Co-Founder & CEO of Palantir Technologies, Alex Karp explores how AI and meritocracy are reshaping the balance of power in the modern world. Drawing from his New York Times best-seller The Technological Republic: Hard Power, Soft Belief, and the Future of the West, which held its spot for 3 weeks and gain…

1
Queer Survival: How AIDS Changed Everything (& What Gen Z Needs to Know) - with Jim Cartwright 1:20:34

9M ago1:20:34

1:20:34

"I'm passionate about collaboration between the generations. We have things to learn from you and you have things to learn from us."Sah is joined by queer elder Jim Cartwright to take listeners on a powerful journey through the AIDS crisis, exploring both its devastating impact and the unexpected gifts that emerged from the darkness. Drawing from h…

1
Creating virtuous cycles in drug development with Rob Freishtat 45:14

9M ago45:14

45:14

Send us a text Rob Freistat, President of Uncommon Cures, discusses how clinical trials are transforming to accelerate drug development and ensure patients receive treatments faster, particularly in the rare disease space. • Current market uncertainty and investment challenges in biotech, especially for rare disease research • Approximately two-thi…

1
Ep. 82 – Act Now or Fall Behind: Michelle Rozo on Biotech’s National Security Stakes 31:01

9M ago31:01

31:01

The U.S. will cede its preeminence in biotechnology to China within three years unless the government acts urgently, an independent commission chartered by Congress warns. “Our window to act is closing,” the National Security Commission on Emerging Biotechnology said in a newly released report. “We need a two-track strategy: make America innovate f…

1
Healing Behind Bars: The Journey of 'The 50’ - with Brenton Gieser 1:06:57

9M ago1:06:57

1:06:57

“It only takes 2% of us to change the entire world.” Sah is joined by Brenton Gieser, the filmmaker behind “The 50,” a documentary about 50 incarcerated men who became substance abuse counselors while in the prison system, for a rich discussion highlighting themes of healing, transformation, and the power of forgiveness. They discuss the profound i…

1
Bridging Academia and Biotech: Creating Innovators of Tomorrow with Jonathon Hill 32:03

9M ago32:03

32:03

Send us a text Jonathan Hill takes us on a fascinating journey through the cutting-edge world of DNA sequencing and its revolutionary potential for early disease detection. As both an academic professor at Brigham Young University and co-founder of Wasatch BioLabs, Hill shares how third-generation sequencing technologies are transforming our abilit…

1
Ep. 81 - Data-Driven Growth: Immunocore CEO Bahija Jallal on Expanding TCR Therapies 30:52

9M ago30:52

30:52

On the latest episode of The BioCentury Show, Editor in Chief Simone Fishburn speaks with Bahija Jallal, CEO of Immunocore and the former president of Medimmune. While some biotechs are circumspect about gathering data during clinical trials that might not support the product in question, Jallal sees it as part of the obligation to patients and the…

1
Grief as Revolution: Reclaiming Our Right to Feel - with J.S. Park 1:16:31

9M ago1:16:31

1:16:31

“Permission to grieve is permission to be human.”Sah is joined by hospital chaplain and author Joon (J.S.) Park to explore the profound art of sitting with suffering in a world obsessed with quick fixes. Drawing from his extensive experience at a Level 1 Trauma Center, J.S. shares the wisdom he's gained from attending countless deaths and supportin…

1
From Lab to Patient: Why Vector Design Makes or Breaks Cell Therapies with Alan Griffith 56:22

10M ago56:22

56:22

Send us a text Vectors are the unsung heroes of cell and gene therapy—molecular couriers that transport therapeutic genes into human cells to treat disease. But as Alan Griffith, Head of Global Operations at Vector Builder reveals, creating these sophisticated delivery vehicles is far more complex than most realize. Drawing from over a decade of ex…

1
Ep. 80 - Vertex’s Winning Formula: Altshuler on Choosing the Next Breakthroughs 32:26

10M ago32:26

32:26

Vertex’s approach to research, defined over a decade ago to beat the dismal odds of success in biotech, remains core to its strategy, even as the industry evolves and technologies expand. While that strategy, which EVP and CSO David Altshuler calls “serial innovation,” has seen the company launch eight drugs since 2011 and jump market cap tiers on …

1
Embracing the Void Space - with Tracee Stanley 1:13:56

10M ago1:13:56

1:13:56

"In the liminal space and that space of doing nothing, there's magic that can happen there."Sah and meditation teacher Tracee Stanley explore the radical power of rest in a world obsessed with productivity. As the bestselling author of "Radiant Rest" and "The Luminous Self," Tracee shares how ancient practices like yoga nidra can transform our rela…

1
Tomorrow's Cures Are Hiding in Today's Patient Records with Vish Srivastava 24:18

10M ago24:18

24:18

Send us a text The untapped potential of electronic health records has long been recognized in clinical research, but extracting meaningful insights from this treasure trove of data has remained an elusive challenge—until now. Vish Srivastava, founder of Century Health, reveals how artificial intelligence is revolutionizing real-world evidence by u…